



Press release

May, 18th 2026

URGO surpasses the €1 billion turnover mark

The family-owned group, a flagship of the ‘Made in France’ movement, is accelerating its international expansion and is set to invest a further €150 million in France by 2027

The URGO Group has announced that, by the end of April, it had achieved a global turnover of one billion euros, thereby joining the select group of French companies to have crossed this symbolic milestone. This is a significant milestone for this 100 per cent family-owned and debt-free company, demonstrating the strength of its business model. Driven by particularly strong international momentum, URGO is reaffirming its growth ambitions, particularly in the United States, where the group forecasts 50 per cent growth over the next two years. At the same time, the group is reaffirming a key strategic choice: to invest in France to innovate, manufacture and create jobs. To this end, it is announcing a €150 million investment plan for 2026–2027, dedicated to research, innovation and the development of its industrial sites in France.

The Urgo model: growth driven by innovation

Operating in over 60 countries with 4,000 employees, the URGO Group – a family-owned business founded in Burgundy in 1880 – has experienced spectacular growth over the last 25 years, with turnover rising from 150 million euros to one billion today.

This trajectory is underpinned by a consistent ability to innovate, both in medical technologies and in industrial processes. URGO invests continuously in research and development to design cutting-edge solutions, now recognised worldwide, particularly in wound care and medical compression. In recent years, this momentum has led to a strategic acceleration, notably through three key acquisitions (Vista-Life Pharma in Belgium, MyBestPharm in Poland and Nutriexperts in Spain), enabling the group to strengthen its market positions and open up new avenues for international growth.

‘Made in France’ works: a driver of appeal and competitiveness

This international success goes hand in hand with an ongoing commitment to the French economy. URGO has chosen to maintain and develop its manufacturing capabilities in France, where nearly 80 per cent of its products are now manufactured. The €150 million investment plan announced for 2026–2027 is fully in line with this approach. It will strengthen the group’s research and development capabilities, particularly in the field of artificial skin, accelerate industrial innovation and modernise its production sites across the country.

This investment programme will have a direct impact on employment, creating jobs across a range of sectors: research, engineering, production and logistics. URGO thus aims to contribute actively to the economic vitality of the regions in which it operates by creating skilled and sustainable jobs.

The group has once again demonstrated that it is possible to build a global leader by drawing on strong local roots, whilst making innovation and the “Made in France” label the driving forces behind its competitiveness and appeal.

Tristan Le Lous, Chairman of the URGO Group, said: *“Crossing the €1 billion turnover threshold is a major milestone. For us, it is above all a source of collective pride and proof of our teams’ strong commitment to our healthcare mission. URGO continues to grow by building on its strengths: innovation and its robust industrial base. We are investing 150 million euros in France over the next two years. As my father would say, today is the first day of the rest of our lives: the URGO adventure has only just begun.”*

About the URGO Group

A French family-owned business founded in 1880 in Burgundy, URGO is now a leading medium-sized enterprise in the healthcare sector, with 4,000 employees worldwide, including 2,000 in France. The Group has experienced rapid growth over the last decade, tripling its turnover to reach €1 billion and expanding its presence to more than 60 countries through 20 subsidiaries. True to its industrial roots, URGO has invested €330 million in R&D and €200 million in its French sites between 2000 and 2025. 80 per cent of its products are now manufactured in France.